

FOI REQUEST NUMBER: 5880

I have a Freedom of Information request, within your Trust in the last 3 months – latest that you have available;

1. In the past three months, how many metastatic hepatocellular carcinoma patients were treated with:

Sorafenib (Nexavar)	5
Other active systemic anti-cancer therapy	0
Other including palliative care	

2. In the past three months, how many metastatic renal cell carcinoma patients were treated with:

Sunitinib (Sutent)	5
Pazopanib (Votrient)	16
Everolimus (Afinitor)	
Temsirolimus (Torisel)	
Cabozantinib (Cometriq) <i>Cabometyx brand</i>	5
Nivolumab (Opdivo)	9
Axinitib (Inlyta)	
Nivolumab + Ipilimumab (Opdivo + Yervoy)	
Levatinib (Lenvima) + Everolimus (Afinitor)	
Tivozanib (Fotivda)	
Other active systemic anti-cancer therapy	
Other including palliative care	

Please note the patients referred to above are being treated for renal cell carcinoma. In order to confirm whether or not they are metastatic we would need to review their clinical information. If we were to do this we would be in breach of the second data protection principle “Personal information must be processed for limited purpose”. We are therefore withholding this information under Section 40 of the Freedom of Information Act.

3. In the past 3 months, how many metastatic melanoma patients were treated with:

<b>Pembrolizumab (Keytruda)</b>	
<b>Nivolumab (Opdivo)</b>	
<b>Ipilimumab (Yervoy)</b>	
<b>Nivolumab + Ipilimumab (Opdivo + Yervoy)</b>	
<b>Dabrafenib + Trametinib (Tafinlar + Mekinist)</b>	
<b>Dabrafenib (Tafinlar)</b>	
<b>Vemurafenib (Zelboraf)</b>	
<b>Vemurafenib + cobimetinib (Zelboraf _ Cotellic)</b>	
<b>Other active systemic anti-cancer therapy</b>	
<b>Other including palliative care</b>	

We do not treat melanoma at this Trust.